LifeVantage (LFVN) reported a solid QQ3 2025 performance driven by the MindBody GLP‑1 system, with revenue of $58.4 million, up 21% year over year. U.S. demand surged 31% while international markets continued to face currency headwinds and weaker activity, contributing to a 7.2% regional decline to $10.2 million in Asia Pacific and Europe. Despite near-term international volatility, the company delivered meaningful margin expansion (gross margin up 210 bps to 81%) and improved profitability, including Adjusted EBITDA of $6.4 million (11% of revenues). Management reaffirmed full-year guidance of revenue in the $228–235 million range and Adjusted EBITDA of $21–24 million, with Adjusted non-GAAP EPS of $0.72–$0.88. LifeVantage also emphasized the LV360 program and the MindBody international rollout as key growth catalysts, including the March 2025 launch into Japan and a planned broader rollout into remaining markets later in 2025. The balance sheet remains robust with $22.5 million of cash and no debt, plus access to a $5 million revolving line of credit, underpinning ongoing investments in growth and shareholder returns (dividends of $0. per share and ongoing buybacks). The QQ3 results underscore a company actively migrating toward higher‑quality, recurring revenue through subscriptions (MindBody now roughly 85% subscription‑based for MB entrants) and a diversified product portfolio, supported by a disciplined capital allocation stance. Investors should note currency sensitivity, execution risk in international markets, and regulatory/macro risks inherent to a direct‑sales nutraceutical model as ongoing considerations.